Skip to main content
. 2015 Apr 21;15(4):9388–9403. doi: 10.3390/s150409388

Figure 1.

Figure 1

Principle behind DDS using a GDDC for cancer therapy. In the absence of a target mRNA in normal cells, the GDDC retains its G-quadruplex structure and thus a G-quadruplex ligand (a telomerase inhibitor) remains bound. In the presence of the target mRNA in cancer cells, the G-quadruplex structure of the GDDC unfolds, releasing the G-quadruplex ligand and inhibiting telomerase activity.